And so, another working week will soon draw to a close. A little quicker than usual, though, yes? Nonetheless, this is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is decidedly modest. We hope to catch up on some reading, run some errands, and take a few strolls about town. And what about you? This is a fine time play catchup yourself, now that the end-of-year festivities have come and gone. This may also be an opportunity to get organized for what may be a busy month. Or perhaps reach out to someone you may have missed recently. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

More drugs are approved in December than any other time of year — but the burst of activity has an unintended side effect: The end-of-year approvals are later associated with more hospitalizations, life-threatening events, and deaths, The Wall Street Journal writes, citing a new study. In the U.S., the number of December drug approvals is roughly 80% larger than in any other month. The surges are not driven by explicit deadlines, leading the researchers to suspect the increases are motivated by self-imposed “desk-clearing” benchmarks.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy